| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US5856529 | VANDA PHARMS INC | Benzofuran and dihydrobenzofuran melatonergic agents |
Dec, 2022
(1 year, 4 months ago) | |
| US10829465 | VANDA PHARMS INC | Highly purified pharmaceutical grade tasimelteon |
Feb, 2035
(10 years from now) | |
| US10071977 | VANDA PHARMS INC | Highly purifid pharmaceutical grade tasimelteon |
Feb, 2035
(10 years from now) | |
| US11566011 | VANDA PHARMS INC | Highly purified pharmaceutical grade tasimelteon |
Feb, 2035
(10 years from now) | |
| US11760740 | VANDA PHARMS INC | Highly purified pharmaceutical grade tasimelteon |
Feb, 2035
(10 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8785492 | VANDA PHARMS INC | Treatment of circadian rhythm disorders |
Jan, 2033
(8 years from now) | |
| US9539234 | VANDA PHARMS INC | Treatment of circadian rhythm disorders |
Jan, 2033
(8 years from now) | |
| USRE46604 | VANDA PHARMS INC | Treatment of circadian rhythm disorders |
Jan, 2033
(8 years from now) | |
| US10945988 | VANDA PHARMS INC | Treatment of circadian rhythm disorders |
Jan, 2033
(8 years from now) | |
| US9855241 | VANDA PHARMS INC | Treatment of circadian rhythm disorders |
Jan, 2033
(8 years from now) | |
| US10449176 | VANDA PHARMS INC | Treatment of circadian rhythm disorders |
Jan, 2033
(8 years from now) | |
| US11633377 | VANDA PHARMS INC | Treatment of circadian rhythm disorders |
Jan, 2033
(8 years from now) | |
| US10610510 | VANDA PHARMS INC | Treatment of circadian rhythm disorders |
Jan, 2033
(8 years from now) | |
| US9060995 | VANDA PHARMS INC | Treatment of circadian rhythm disorders |
Jan, 2033
(8 years from now) | |
| US10980770 | VANDA PHARMS INC | Treatment of circadian rhythm disorders |
Jan, 2033
(8 years from now) | |
| US11850229 | VANDA PHARMS INC | Treatment of circadian rhythm disorders |
Jan, 2033
(8 years from now) | |
| US11833130 | VANDA PHARMS INC | Treatment of circadian rhythm disorders |
Jan, 2033
(8 years from now) | |
| US10149829 | VANDA PHARMS INC | Treatment of circadian rhythm disorders |
Jan, 2033
(8 years from now) | |
| US11285129 | VANDA PHARMS INC | Treatment of circadian rhythm disorders |
Jan, 2033
(8 years from now) | |
| US9549913 | VANDA PHARMS INC | Treatment of circadian rhythm disorders |
Jan, 2033
(8 years from now) | |
| US9730910 | VANDA PHARMS INC | Treatment of circadian rhythm disorders |
May, 2034
(10 years from now) | |
| US11786502 | VANDA PHARMS INC | Method of treatment |
Oct, 2034
(10 years from now) | |
| US10610511 | VANDA PHARMS INC | Method of treatment |
Oct, 2034
(10 years from now) | |
| US11141400 | VANDA PHARMS INC | Method of treatment |
Oct, 2034
(10 years from now) | |
| US10376487 | VANDA PHARMS INC | Method of treatment |
Jul, 2035
(11 years from now) | |
| US10179119 | VANDA PHARMS INC | Method of treatment |
Aug, 2035
(11 years from now) | |
| US11266622 | VANDA PHARMS INC | Method of treatment |
Aug, 2035
(11 years from now) | |
| US11759446 | VANDA PHARMS INC | Liquid tasimelteon formulations and methods of use thereof |
Feb, 2041
(16 years from now) | |
Hetlioz is owned by Vanda Pharms Inc.
Hetlioz contains Tasimelteon.
Hetlioz has a total of 28 drug patents out of which 1 drug patent has expired.
Expired drug patents of Hetlioz are:
- US5856529
Hetlioz was authorised for market use on 31 January, 2014.
Hetlioz is available in capsule;oral dosage forms.
Hetlioz can be used as treatment of non-24 hour sleep-wake disorder by orally administering 20mg of tasimelteon once daily before bedtime, treatment of non-24 hour sleep-wake disorder by avoiding the administration of tasimelteon with food, treatment of non-24 hour sleep-wake disorder by administering tasimelteon, treatment of non-24 hour sleep-wake disorder by administering tasimelteon to patients with a smoking history, treatment of nighttime sleep disturbances in smith-magenis syndrome non-24 hour sleep-wake disorder by avoiding the use of tasimelteon in combination with cyp1a2 strong inhibitors, treatment of non-24-hour sleep-wake disorder by avoiding the administration of tasimelteon with food, treatment of nighttime sleep disturbances in smith-magenis syndrome by administering tasimelteon, treatment of nighttime sleep disturbances in smith-magenis syndrome by avoiding the administration of tasimelteon with food, treatment of non-24-hour sleep-wake disorder by avoiding the administration of tasimelteon with beta-adrenergic receptor antagonists, treatment of nighttime sleep disturbances in smith-magenis syndrome by avoiding the avoiding the use of tasimelteon in combination with a strong cyp1a2 inhibitor, treatment of non-24 hour sleep-wake disorder by avoiding the administration of tasimelteon to smokers or to patients being treated with a cyp1a2 inhibitor, treatment of non-24-hour sleep-wake disorder, treatment of nighttime sleep disturbances in smith-magenis syndrome by avoiding the use of tasimelteon with rifampin, treatment of non-24-hour sleep-wake disorder by avoiding the use of tasimelteon in combination with fluvoxamine.
Drug patent challenges can be filed against Hetlioz from 31 January, 2018.
The generics of Hetlioz are possible to be released after 21 February, 2041.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE-330) | Dec 01, 2027 |
| Orphan Drug Exclusivity(ODE) | Jan 31, 2021 |
| New Indication(I-850) | Dec 01, 2023 |
| New Chemical Entity Exclusivity(NCE) | Jan 31, 2019 |
| Orphan Drug Exclusivity(ODE-59) | Jan 31, 2021 |
Drugs and Companies using TASIMELTEON ingredient
NCE-1 date: 31 January, 2018
Market Authorisation Date: 31 January, 2014
Treatment: Treatment of non-24-hour sleep-wake disorder; Treatment of nighttime sleep disturbances in smith-magenis syndrome by avoiding the avoiding the use of tasimelteon in combination with a strong cyp1a2 in...
Dosage: CAPSULE;ORAL
HETLIOZ family patents
